Selank has been tested in a few small human studies for anxiety, but those studies do not establish how reliably it helps or whether it is safe for long-term use. Selank is a laboratory-made peptide, a chain of seven amino acids (the small building blocks of proteins). It is based on part of an immune-system molecule called tuftsin. Researchers in Russia developed it as a possible treatment for anxiety and related symptoms.
The published human evidence is much smaller than the online conversation suggests. A handful of clinical reports have compared Selank with older anxiety medicines, and one brain-imaging study examined short-term effects in healthy volunteers. Much of the remaining research involves rats, mice, isolated tissue, or cells. Those studies can suggest how a compound might work. They cannot tell us that an internet product will treat anxiety, improve memory, or be safe over months or years.
Why researchers became interested in Selank
Scientists often begin with a biological clue. Selank resembles a fragment of tuftsin, a peptide involved in immune activity. Researchers asked whether changing that fragment might produce effects in the nervous system. Anxiety is influenced by networks of brain cells that respond to many chemical signals. One is GABA, which generally helps quiet nerve-cell activity. Others include small signaling molecules called enkephalins. Selank studies have investigated both pathways, along with changes in inflammation and gene activity.
None of these pathways, by itself, establishes a treatment effect. A medicine can attach to a receptor in a dish and still fail to help people. A study can also show that a person's brain activity changes after receiving a substance without showing that their anxiety improves. Keeping those distinctions in mind makes the clinical studies easier to judge.
The 2008 comparison with medazepam: 62 patients
One of the most relevant human papers is the 2008 study by Zozulia and colleagues (https://pubmed.ncbi.nlm.nih.gov/18454096/). It enrolled 62 people described as having generalized anxiety disorder or neurasthenia, a historical diagnosis associated with fatigue and distress. Thirty received Selank and 32 received medazepam, a benzodiazepine anxiety medicine. The PubMed record classifies the report as a randomized controlled trial. Researchers followed symptoms with standard rating scales, including the Hamilton and Zung scales and a clinician's overall impression. They also measured activity of leu-enkephalin in blood serum.
The abstract says the two treatments had similar anti-anxiety effects. It also reports improvements in fatigue-like symptoms and stimulation with Selank. The researchers saw changes in the blood measure during treatment, particularly among patients with generalized anxiety disorder. This study describes actual patients and an active comparison group. The English abstract does not give numerical symptom changes for each group, a confidence interval for their difference, or enough detail to independently judge the randomization, masking, and side-effect collection. The full paper is in Russian and should be checked before making a stronger claim.
There is another important design point. Comparing a new treatment with an existing drug does not answer the same question as comparing it with an inactive placebo. Anxiety ratings can improve over time for many reasons, including natural fluctuation, attention from clinicians, and expectations. If two groups improve similarly, the result can be encouraging, but a small trial without a clearly reported placebo arm cannot, on its own, prove that Selank caused the change. It also cannot establish that Selank is equivalent to medazepam: a proper equivalence study must be designed and powered to test a prespecified acceptable difference.
The enkephalin result is a useful hypothesis about mechanism, not an independent clinical benefit. A blood marker is not the same thing as a person sleeping better, returning to work, or experiencing fewer panic symptoms.
The 2014 comparison with phenazepam: 60 patients
A 2014 clinical report by Medvedev and colleagues (https://pubmed.ncbi.nlm.nih.gov/25176261/) compared Selank with phenazepam in 60 people with phobic anxiety and somatoform disorders. A somatoform disorder is an older diagnostic category in which physical symptoms are closely connected with psychological distress. The abstract reports a reduction in anxiety, a mild effect on thinking-related measures, improved quality of life, and an anti-anxiety effect that persisted for a week after the last Selank administration.
Those are potentially interesting observations, especially the follow-up after treatment ended. Yet the accessible abstract does not provide the group-by-group numbers, size of benefit, adverse-event counts, or enough information about allocation and blinding. It is not possible from this summary to tell whether a small difference between treatments was meaningful to patients or whether the results would hold up in a larger trial. A week of follow-up also tells us little about repeated use over months.
Phenazepam is a sedating benzodiazepine. If one treatment causes obvious sedation and the other does not, participants and clinicians may guess which treatment was given even when a study is formally described as blinded. That matters when outcomes include subjective ratings of anxiety and well-being. The study should be read as a small comparison that invites replication, not as proof that Selank is a better established choice.
The 2015 add-on study: Selank plus phenazepam
The next Medvedev group report, published in 2015 (https://pubmed.ncbi.nlm.nih.gov/26356395/), asked a different question. Thirty patients received phenazepam alone, while 40 received phenazepam together with Selank. The authors used symptom scales, quality-of-life measures, and tests of attention and verbal fluency. They reported an earlier improvement on one rating scale in the combined-treatment group and less of several unwanted effects they attributed to phenazepam, including sedation, attention and memory problems, and fatigue.
This does not show what Selank does when taken by itself. It tests a combination against a single medicine, and the accessible abstract does not establish whether all other aspects of care were identical or provide the detailed numbers needed to judge the magnitude of each effect. The results are also difficult to generalize to people taking other medications or to those with no diagnosed anxiety condition. Even if the add-on finding is real, it would need a larger independent trial to show how reliably it occurs and which patients benefit.
Read together, the three clinical reports offer a modest signal that Selank deserves further study for anxiety. They are not three large, independent confirmations. The teams and clinical settings overlap, the papers are small, and much of the detailed methodology is hard for an English-language reader to inspect. There is no strong published evidence here for depression, attention-deficit disorder, insomnia, or broad "brain optimization," regardless of how often those uses are advertised.
A brain-imaging study is not a treatment trial
A 2020 experiment by Panikratova and colleagues (https://pubmed.ncbi.nlm.nih.gov/32342318/) studied brain network activity in 52 healthy volunteers after Selank, a related peptide called Semax, or placebo. Researchers used functional MRI, a scan that measures changes linked to blood flow as an indirect sign of brain activity. They looked at patterns of communication between brain regions shortly after administration, including observations at about five and twenty minutes. The study reported differences in connectivity patterns.
This adds a different kind of evidence: Selank may have measurable short-term effects in the human brain. It does not show that the participants had an anxiety disorder, that their symptoms improved, or that a longer course would help. Brain scans can be sensitive to small changes whose everyday meaning is unknown. They cannot replace a trial that asks patients how they feel and function over time. Nor should a connectivity change be translated into a claim of improved memory or emotional control without direct tests of those outcomes.
What the laboratory studies suggest
An early 2001 enzyme experiment (https://pubmed.ncbi.nlm.nih.gov/11550013/) investigated whether Selank affected enzymes that break down enkephalins, small molecules involved in signaling and pain or stress responses. This was a biochemical investigation, not a patient trial. It helps explain why the 2008 investigators measured enkephalin-related activity, but it cannot tell us how much Selank reaches a person's brain after a given product or whether this pathway accounts for symptom changes.
In a 2008 rat experiment (https://pubmed.ncbi.nlm.nih.gov/18841804/), researchers examined hippocampal brain-derived neurotrophic factor, often shortened to BDNF. BDNF is a protein involved in the growth and maintenance of nerve-cell connections. A change in this marker can be biologically interesting, but it is not the same as repairing a person's brain or improving their memory. The animals, dose, and timing were specific to the experiment. Human benefits require human outcome studies.
A 2018 study using rat-brain membrane preparations (https://pubmed.ncbi.nlm.nih.gov/30255741/) tested how Selank influenced the binding of GABA to receptors. The authors reported a pattern consistent with positive allosteric modulation. In plain language, that means Selank changed how a receptor responded to another substance without necessarily occupying the same site. The paper also reported interactions with diazepam and olanzapine in this laboratory system. This is a possible mechanism, not evidence that Selank has the same effect or safety profile as a benzodiazepine in people. A receptor experiment cannot predict withdrawal risk, driving impairment, or the result of mixing substances in real life.
The 2017 experiment in human-derived neuroblastoma cells (https://pubmed.ncbi.nlm.nih.gov/28293190/) is especially useful because it resists an oversimplified story. The researchers examined expression of selected genes related to nervous-system signaling. Selank alone did not change the measured messenger-RNA levels in the way the other tested conditions did; it altered some responses when combined with GABA or olanzapine. Messenger RNA is a temporary set of instructions cells use to make proteins. A cell line grown in a dish is not a living brain, and a changed instruction signal is not a demonstrated clinical outcome. The result supports further investigation of interactions, while showing why it is misleading to say that Selank simply "switches on" a set of beneficial brain genes.
A 2021 mouse study of social stress (https://pubmed.ncbi.nlm.nih.gov/32621722/) investigated inflammatory signaling molecules, called cytokines. Researchers reported changes after Selank in stressed animals. Inflammation and stress do influence each other, but mouse social-stress models are simplified versions of human experience. This result does not demonstrate that Selank treats an inflammatory condition or prevents chronic stress damage in people. It is one more possible biological lead.
These examples cover the main clinical claims and several distinct research approaches: enzymes, brain-growth signaling, GABA receptor behavior, gene expression, and immune signals. Other preclinical Selank publications exist. Their number should not be mistaken for the number of independent human demonstrations of benefit.
What is still unknown about safety and everyday use
Small studies can miss uncommon harms. A trial with 30 or 60 people cannot reliably detect a problem that happens in one of several hundred users. The published clinical abstracts also do not establish long-term safety, effects in pregnancy or breastfeeding, or interactions with sedatives, alcohol, or other medicines. A report of fewer phenazepam side effects in one add-on study should not be converted into a promise that Selank is free of side effects.
Product quality adds another uncertainty. A research study uses a particular preparation and administration method. A vial or spray sold online may differ in identity, purity, concentration, storage history, or labeling. Even a real study benefit would not automatically carry over to every commercial preparation. The existence of a chemical record or a paper does not mean a product has passed the approval process in a reader's country.
For a person living with anxiety, this distinction matters. Anxiety can be disruptive and sometimes signals another medical or mental-health issue. Stopping prescribed treatment or combining an unverified peptide with sedating medication based on an online claim could create problems that the Selank trials were not designed to study. The practical question to bring to a qualified clinician is not simply "Does Selank work?" but which well-tested options fit the person's symptoms, medical history, and goals.
A fair reading of the evidence
Selank is a genuine research subject, with three small published clinical reports relevant to anxiety and one short-term human brain-imaging experiment. The clinical reports suggest possible benefit, but accessible reporting does not let readers confidently estimate its size, compare it with placebo, or judge long-term risks. Laboratory and animal experiments offer several plausible pathways without proving that any one pathway produces a useful effect in people.
The clearest next step for research is a larger, independently run trial that randomly assigns people with a well-defined anxiety condition to Selank or placebo, uses convincing masking, reports patient-important outcomes and adverse events in full, and follows participants long enough to assess whether benefits last. Until that exists, Selank is best understood as a promising but incompletely tested peptide, rather than an established answer to anxiety.
